Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 245

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 6
Chunk 245
---
. We generally provide our employees with benefits and working conditions beyond the required minimums.
 
We have never experienced any employment-related work stoppages and believe our relationship with our employees is good.
 

E. Share Ownership
 
 See “Item 7.A. Major Shareholders” below.

Equity Compensation Plan
 
2003 Amended and Restated Share Incentive Plan
 
In 2003, we adopted the BioLineRx Ltd. 2003 Share Incentive Plan, or the Plan. In August 2013, our board of directors approved certain amendments to the Plan and extended the term of the Plan until November 2023, and the Plan was renamed as the BioLineRx Ltd. 2003 Amended and Restated Share Incentive Plan. In January 2016, our board of directors approved amendments to the Plan in order to permit the granting RSUs and PSUs to eligible grantees. In November 2023, our board of directors approved a six-month extension of the term of the Plan until May 2024 and, in May 2024, our board of directors approved a further extension until May 2044. References below to the “Plan” refer to the Plan as amended in August 2013, January 2016, November 2023 and May 2024.
 
 The Plan provides for the granting of options, ordinary shares, RSUs and PSUs to our directors, employees, consultants and service providers, and to the directors, employees, consultants and service providers of our subsidiaries and affiliates. The Plan provides for equity grants to be made at the determination of our board of directors in accordance with applicable law. As of March 16, 2025, options to purchase 107,746,200 ordinary shares or 179,577 ADSs, an aggregate 13,832,400 PSUs or 23,054 ADSs and an aggregate of 9,588,600 RSUs or 15,981 ADSs were outstanding under the Plan.

  From time to time, our board of directors has approved an increase in the number of shares reserved for the purpose of equity grants pursuant to the Plan. As of March 16, 2025, 68.9 million ordinary shares, or 0.1 million ADSs, were reserved for future issuance under the Plan.

The Plan is administered by our board of directors for the purposes of making equity grants and approving the terms of those grants, including, exercise price (in the case of options),